Pioneering Advancements in the Pulmonary
senior management team and the Board of Directors have in-depth expertise
and experience in the management and oversight of public health care
companies and in bringing a variety of pharmaceutical and health care
products to market in the U.S.
and internationally. Members of the company's Scientific Advisory Board are
among the world's leading experts in pulmonary medicine and inhalation drug
delivery. Together, this leadership team is pioneering important
advancements in the respiratory sector of the pharmaceutical industry and
positioning Aradigm as a new leader in the specialty pharmaceutical market.
Igor Gonda, Ph.D.
& Chief Executive Officer
Dr. Gonda has served as President and Chief Executive Officer since
August 2006, and as a director since September 2001. From December 2001
to August 2006, Dr. Gonda was the Chief Executive Officer and Managing
Director of Acrux Limited, a publicly traded specialty pharmaceutical
company located in Melbourne, Australia.
From July 2001 to December 2001, Dr. Gonda was our Chief Scientific
Officer and, from October 1995 to July 2001, was our Vice President,
Research and Development. From February 1992 to September 1995, Dr. Gonda
was a Senior Scientist and Group Leader at Genentech, Inc. leading
inhalation development of products for severe respiratory disease. Prior
to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom,
and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in
Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom.
Dr. Gonda was the Chairman of our Scientific Advisory Board until August
Chief Financial Officer
Ms. Pecota has more than 20 years of experience in corporate accounting
and operations management. She previously served as Chief Financial
Officer for NuGEN Technologies, Inc., a life sciences tools company that
provides specialty reagents to pharmaceutical and diagnostics companies.
Prior to that she served as a financial consultant to early- and
mid-stage life sciences companies, developing fundable business models
and assessing and improving internal financial preparation and reporting
processes. She has served as Vice President, Finance and Administration
at Signature BioScience, Inc., a venture-backed biopharmaceutical
company; and as Director, Finance and Accounting for ACLARA BioSciences,
Inc., a biotechnology company. Ms. Pecota holds a Bachelor of Science in
Economics from San Jose
and was among the executives named in the San Francisco Business Times
"100 Most Influential Bay Area Business Women" in 2002 and
Board of Directors
Virgil D. Thompson
Chairman of the Board, Aradigm Corporation;
CEO of Spinnaker Biosciences, Inc.
Frank H. Barker
Former Group Chairman, Johnson & Johnson
Igor Gonda, Ph.D.
President & Chief Executive Officer, Aradigm Corporation
Dr. John M. Siebert
Former Chairman & Chief Executive Officer, CyDex, Inc.;
Former CEO of CIMA Labs
Helen E. Short
Former Vice President of Investor Relations, Johnson & Johnson,
Aradigm's Scientific Advisory Board is a highly
regarded team of scientific experts who help the Company with strategic
input into the development of treatments for severe respiratory disease,
and in pharmaceutical development and pulmonary drug delivery in general.
The group assists the company on a variety of issues related to potential
product applications, product development paths and clinical testing.
Peter R. Byron, Ph.D.
Medical College of Virginia,
Virginia Commonwealth University
Expertise: Aerosol Science/Pharmaceutics
Peter S. Creticos, M.D.
The Johns Hopkins University
School of Medicine
Stephen J. Farr, Ph.D.
Expertise: Pulmonary Delivery/Pharmaceutics
Tunde Otulana , M.D.
Expertise: Pulmonary Medicine,
Adam Wanner, Ph.D.
University of Miami
Expertise: Chronic Obstructive Pulmonary Disease (COPD)
addition to this Scientific Advisory Board, the Company also engages other
scientific and medical experts to assist on issues specific to particular indications